Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 8, 2022

Primary Completion Date

June 8, 2027

Study Completion Date

June 8, 2027

Conditions
Adrenocortical Carcinoma
Interventions
DRUG

Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG

"EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days.~Megestrol acetate will be prepared and packaged by the authorized external contract development and manufacturing organization (CDMO) Doppel Farmaceutici s.r.l. (Cortemaggiore, PC), that, according to the GMP and applicable law (FU XII ed) will also prepare the related placebo, in accordance with GMP (annex 13) and applicable law (FU XII ed.)."

DRUG

Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo

EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Placebo 160 mg tablets will be developed by the CDMO to have the same appearance and taste as the tablet containing the active drug.

Trial Locations (1)

25123

RECRUITING

Alfredo Berruti, Brescia

All Listed Sponsors
lead

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

OTHER